JP2010531825A - 血管作動性物質とエストロゲンとの組合せ、および女性の性機能障害の治療におけるその使用 - Google Patents
血管作動性物質とエストロゲンとの組合せ、および女性の性機能障害の治療におけるその使用 Download PDFInfo
- Publication number
- JP2010531825A JP2010531825A JP2010513754A JP2010513754A JP2010531825A JP 2010531825 A JP2010531825 A JP 2010531825A JP 2010513754 A JP2010513754 A JP 2010513754A JP 2010513754 A JP2010513754 A JP 2010513754A JP 2010531825 A JP2010531825 A JP 2010531825A
- Authority
- JP
- Japan
- Prior art keywords
- hydroxyethyl
- extract
- icaritin
- fertinin
- forskolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title claims description 9
- 206010057671 Female sexual dysfunction Diseases 0.000 title claims description 5
- 230000002227 vasoactive effect Effects 0.000 title claims description 4
- 239000000126 substance Substances 0.000 title description 7
- 239000000262 estrogen Substances 0.000 title description 2
- 229940011871 estrogen Drugs 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 27
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims abstract description 26
- TUUXBSASAQJECY-UHFFFAOYSA-N 3,5,7-trihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chromen-4-one Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C(CC=C(C)C)=C2O1 TUUXBSASAQJECY-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 17
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims abstract description 14
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims abstract description 13
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims abstract description 13
- CTGVBHDTGZUEJZ-UHFFFAOYSA-N Noricaritin Natural products CC(C)(O)CCC1=C(O)C=C(O)C(C(C=2O)=O)=C1OC=2C1=CC=C(O)C=C1 CTGVBHDTGZUEJZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000001671 coumarin Nutrition 0.000 claims abstract description 9
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims abstract description 7
- 239000003075 phytoestrogen Substances 0.000 claims abstract description 7
- 241000510609 Ferula Species 0.000 claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- FRBORWNVTCITAQ-NDMJEZRESA-N Ferulin Chemical compound C1=C2C(C)=CC(=O)C2=C(C)C[C@@H]2OC(=O)[C@@H](C)[C@H]21 FRBORWNVTCITAQ-NDMJEZRESA-N 0.000 claims abstract description 4
- ZCQUVYYTTJUIOH-UHFFFAOYSA-N anhydroaustricin Natural products CC1C2C=CC(=C3C(C2OC1=O)C(=CC3=O)C)C ZCQUVYYTTJUIOH-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000004775 coumarins Chemical class 0.000 claims abstract description 4
- FRBORWNVTCITAQ-UHFFFAOYSA-N ferulin Natural products C1=C2C(C)=CC(=O)C2=C(C)CC2OC(=O)C(C)C21 FRBORWNVTCITAQ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 9
- 235000020242 coleus extract Nutrition 0.000 claims description 5
- 229960000956 coumarin Drugs 0.000 claims description 5
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000007903 gelatin capsule Substances 0.000 claims description 3
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 claims description 2
- GUAFOGOEJLSQBT-UHFFFAOYSA-N aesculetin dimethyl ether Natural products C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 claims description 2
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 claims description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 2
- 229940044950 vaginal gel Drugs 0.000 claims description 2
- 239000000029 vaginal gel Substances 0.000 claims description 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 229940120293 vaginal suppository Drugs 0.000 claims 1
- 239000006216 vaginal suppository Substances 0.000 claims 1
- 230000001457 vasomotor Effects 0.000 abstract description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 7
- 230000001568 sexual effect Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 241000533992 Ferula communis Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005461 lubrication Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- 241000131459 Plectranthus barbatus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000004392 genitalia Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- 235000005320 Coleus barbatus Nutrition 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001313288 Labia Species 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- GVBNSPFBYXGREE-CXWAGAITSA-N Visnadin Chemical compound C1=CC(=O)OC2=C1C=CC1=C2[C@@H](OC(C)=O)[C@@H](OC(=O)[C@H](C)CC)C(C)(C)O1 GVBNSPFBYXGREE-CXWAGAITSA-N 0.000 description 2
- GVBNSPFBYXGREE-UHFFFAOYSA-N Visnadine Natural products C1=CC(=O)OC2=C1C=CC1=C2C(OC(C)=O)C(OC(=O)C(C)CC)C(C)(C)O1 GVBNSPFBYXGREE-UHFFFAOYSA-N 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003029 clitoris Anatomy 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000005225 erectile tissue Anatomy 0.000 description 2
- -1 hydroxyethyl icaritin Chemical compound 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 230000035936 sexual power Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- BBMFSGOFUHEVNP-UHFFFAOYSA-N 4-hydroxy-2-methylbenzoic acid Chemical compound CC1=CC(O)=CC=C1C(O)=O BBMFSGOFUHEVNP-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001536358 Fraxinus Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- IYCPMVXIUPYNHI-UHFFFAOYSA-N Icariside I Natural products C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 IYCPMVXIUPYNHI-UHFFFAOYSA-N 0.000 description 1
- NGMYNFJANBHLKA-SENBMHEBSA-N Icariside II Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O)c(C/C=C(\C)/C)c3O2)cc1 NGMYNFJANBHLKA-SENBMHEBSA-N 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000005226 corpus cavernosum Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- NGMYNFJANBHLKA-LVKFHIPRSA-N icariside II Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O)C(CC=C(C)C)=C2O1 NGMYNFJANBHLKA-LVKFHIPRSA-N 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
- 229960000821 visnadine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、オルガズムの減少および/または膣の潤滑不足に伴う性機能障害の治療に有用である、末梢血液循環に作用する物質と植物エストロゲンとの組合せに関する。有効成分は、クマリンおよびジテルペン、またはそれらを含有する抽出物、ならびに特定の抗ホスホジエステラーゼ活性を発揮するフラボノイドから選択した。これらの物質の組合せは、女性器に施されることになり、有効成分の迅速な吸収を補助し、オルガズムおよび性的能力の改善、ならびに欲求の誘発に寄与する賦形剤を含む、適切な製剤に組み込まれる。
***の最適化、即ち***および生理的潤滑の改善が、特定のホスホジエステラーゼの阻害を介した動脈循環および静脈拡張を活性化する物質と、エストラゲンとの組合せの局所適用により、実質的に得られることが判明した。
血管運動性(vasokinetic)天然クマリン、
3,7−O−ジ−(2−ヒドロキシエチル)イカリチン(icaritin)もしくは7−O−ヒドロキシエチル−イカリシド(icariside)II、および/またはホルスコリン、あるいはそれらを含有する抽出物から選択される抗ホスホジエステラーゼ剤、
フェルチニンもしくはFerula種のフェルチニン含有抽出物またはp−ピバロイルフェルチニンから選択されるフィトエストロゲン
を含む。
ビスナジン 1%
Coleus forskohlii抽出物>80% 0.25%
3,7−O−ヒドロキシエチル−イカリチン
(3,7−O−hydroxyethyl ikaritina)0.2%
Ferula communis抽出物40% 0.25%
ヒドロキシエチルセルロース 3%
ポリソルベート80 3%
p−ヒドロキシ−メチルベンゾエート 0.1%
プロピレングリコール 〜100。
ビスナジン 10.0mg
Coleus forskohlii抽出物>80% 2.0mg
3,7−O−ヒドロキシエチル−イカリチン 5.0mg
Ferula communis抽出物 8.0mg
ポリエチレングリコールパルミトイル−ステアレート 80.0mg
ポリオキシエチレングリセリド 60.0mg
安息香酸 5.0mg
ブチルヒドロキシアニソール 0.5mg
ワセリン油 450.0mg
精製水 〜3.0g。
ビスナジン 10.0mg
Coleus forskohlii抽出物>80% 2.0mg
3,7−O−ヒドロキシエチル−イカリチン 5.0mg
Ferula communis抽出物 8.0mg
ポリソルベート 100mg
PEG600q.b.a 600.0mg。
炭酸カリウム145g、2−ブロモエタノール39mL(68g)およびテトラブチルアンモニウムブロミド5.4gを、アセトン1.95L中のイカリチン27gの溶液に加えた。反応混合物を40℃で20時間撹拌し、次いでブフナー漏斗で濾過した。ケーキをアセトン(300mL)で洗浄した。有機相を合わせて、減圧下で蒸発させた。粗製物を沸騰アセトニトリル250mLに溶解し、放置して室温で冷却し、次いで4℃で終夜冷蔵した。沈殿物を減圧下で濾過し、アセトン30mLで洗浄した。白色固体(10g)として生成物が得られた。
無水炭酸カリウム137.5g、テトラブチルアンモニウムブロミド5gおよび2−ブロモエタノール35mLを、アセトン3.12L中のイカリシドII25gの懸濁液に加えた。混合物を40℃で撹拌した。1日後、反応を完了した。粗製混合物をセライトで濾過し、無機塩を除去し、ケーキをアセトン(100mL)およびメタノール/アセトン溶液(1:10、200mL)で洗浄した。有機相を収集し、減圧下で蒸発させた。残渣(55g)を酢酸エチル1Lに溶解した。溶液を水で2回(各々1Lおよび0.3L)洗浄した。水層を酢酸エチル0.3Lで抽出した。有機層を収集し、水0.2Lでもう一度洗浄し、Na2SO4上で乾燥し、濾過して、減圧下で蒸発させた。白色固体として生成物が得られた(14.3g)。
MS m/z 581(M+1)。Mp 194〜96(エタノール)。
Claims (9)
- 血管運動性天然クマリンまたはそれらを含有する抽出物、
3,7−O−ジ−(2−ヒドロキシエチル)イカリチンもしくは7−O−ヒドロキシエチル−イカリシドII、および/またはホルスコリン、あるいはそれらを含有する抽出物から選択される抗ホスホジエステラーゼ剤、
フェルチニンもしくはFerula種のフェルチニン含有抽出物またはp−ピバロイルフェルチニンから選択されるフィトエストロゲン、
を含む組成物。 - 前記天然クマリンが、ビスナジン、エスクレチン、エスクロシドから選択される、請求項1に記載の組成物。
- 3,7−O−ジ−(2−ヒドロキシエチル)イカリチンとホルスコリンまたはColeus forskohlii抽出物との両方を含む、請求項1または2に記載の組成物。
- 前記フィトエストロゲンが、フェルチニンまたはそれを含有するFerula種の抽出物から選択される、請求項1から3のいずれかに記載の組成物。
- 膣ゲルまたは軟ゼラチンカプセルまたは膣用坐剤(ovule)の形態の、請求項1から4のいずれかに記載の組成物。
- 女性の性機能障害の治療のための薬剤または医療用具の調製のための、
血管運動性天然クマリンまたはそれらを含有する抽出物、
3,7−ヒドロキシエチルイカリチンもしくはその誘導体、および/またはホルスコリン、あるいはそれらを含有する抽出物から選択される抗ホスホジエステラーゼ剤、
フェルチニンもしくはFerula種のフェルチニン含有抽出物またはp−ピバロイルフェルチニンから選択されるフィトエストロゲン、
を組合せた使用。 - 3,7−O−ジ−(2−ヒドロキシエチル)イカリチンまたは7−O−ヒドロキシエチル−イカリシドIIから選択される化合物。
- cGMPホスホジエステラーゼ阻害剤としての請求項7の化合物。
- 女性の性機能障害の治療のための請求項7の化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07012989A EP2011496A1 (en) | 2007-07-03 | 2007-07-03 | Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions |
EP07012989.5 | 2007-07-03 | ||
PCT/EP2008/005191 WO2009003631A1 (en) | 2007-07-03 | 2008-06-26 | Combinations of vasoactive substances with estrogens and their use in the treatment of female sexual dysfunctions |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010531825A true JP2010531825A (ja) | 2010-09-30 |
JP5386483B2 JP5386483B2 (ja) | 2014-01-15 |
Family
ID=38729005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010513754A Expired - Fee Related JP5386483B2 (ja) | 2007-07-03 | 2008-06-26 | 血管作動性物質とエストロゲンとの組合せ、および女性の性機能障害の治療におけるその使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8211479B2 (ja) |
EP (1) | EP2011496A1 (ja) |
JP (1) | JP5386483B2 (ja) |
KR (1) | KR101529306B1 (ja) |
CN (1) | CN101720223B (ja) |
AU (1) | AU2008271573B2 (ja) |
CA (1) | CA2691943A1 (ja) |
IL (1) | IL203063A (ja) |
NO (1) | NO20100528L (ja) |
RU (1) | RU2478382C2 (ja) |
WO (1) | WO2009003631A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016513680A (ja) * | 2013-03-15 | 2016-05-16 | ワーナー チルコット カンパニー, エルエルシーWarner Chilcott Company, Llc | 医薬ソフトゼラチンカプセル剤形 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552995A (zh) * | 2010-12-07 | 2012-07-11 | 宁小静 | 人体润滑剂 |
US8940794B2 (en) | 2011-04-07 | 2015-01-27 | Nexmed Holdings, Inc. | Methods and compositions for treating Raynaud's disease |
CN104688724B (zh) * | 2013-12-04 | 2019-10-01 | 鲁南制药集团股份有限公司 | 淫羊藿苷元在制备抗疲劳药物中的应用 |
WO2016003536A1 (en) * | 2014-06-30 | 2016-01-07 | Salix Pharmaceuticals, Inc. | Methods for retreating irritable bowel syndrome (ibs) |
CN104387430B (zh) * | 2014-10-27 | 2017-03-15 | 广东东阳光药业有限公司 | 淫羊藿苷类化合物及其应用 |
CN104529974B (zh) * | 2014-12-12 | 2017-01-04 | 广东东阳光药业有限公司 | 淫羊藿苷类化合物及其应用 |
KR102242033B1 (ko) | 2018-01-12 | 2021-04-20 | 주식회사 보타메디 | 플로로탄닌을 유효성분으로 포함하는 여성 성기능 개선용 조성물 |
EP4188362A1 (en) * | 2020-08-03 | 2023-06-07 | Agora' Pharma S.r.l. | Gynaecological compositions based on cannabidiol and terpenes in combination with peripheral vasodilators |
CN114671840B (zh) * | 2021-12-30 | 2023-03-28 | 西安岳达生物科技股份有限公司 | 一种淫羊藿苷衍生物的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005004890A1 (en) * | 2003-07-11 | 2005-01-20 | Indena S.P.A. | Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions |
WO2006042409A1 (en) * | 2004-10-20 | 2006-04-27 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women |
WO2006113242A2 (en) * | 2005-04-13 | 2006-10-26 | Unimed Pharmaceuticals, Inc. | Method of increasing testosterone and related steroid concentrations in women |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4205200A (en) * | 1977-10-04 | 1980-05-27 | Ncr Corporation | Digital communications system utilizing controllable field size |
US20050100618A1 (en) * | 1999-07-01 | 2005-05-12 | Thompson Ronald J. | Method of using a compound of menthol and L-arginine as a preparation for the topical delivery of Icariin, a herbal product produced from the Epimedium genus of the Berberidaceal family of plants, for the treatment of sexual dysfunction |
US6989163B2 (en) * | 2001-10-23 | 2006-01-24 | 40 J's Llc | Arrangement to enhance a woman's sexual sensitivity by a combination of phytoestrogens, L-arginine and menthol |
FR2822333B1 (fr) * | 2001-03-15 | 2003-07-04 | Cit Alcatel | Procede de configuration de parametres pour une transmission par paquets de donnees |
US6623768B1 (en) * | 2002-04-16 | 2003-09-23 | Yousry M. A. Naguib | Pharmaceutically active composition extracted from Ferula hermonis and process of its extraction |
ITMI20020994A1 (it) * | 2002-05-10 | 2003-11-10 | Indena Spa | Formulazioni utili nel trattamento dell'impotenza maschile e femminile |
ITMI20031427A1 (it) * | 2003-07-11 | 2005-01-12 | Indena Spa | Combinazioni di agenti vasoattivi, loro uso in campo farmaceutico e cosmetico e formulazioni che li contengono |
US7684374B2 (en) * | 2004-07-28 | 2010-03-23 | Broadcom Corporation | Handling of multimedia call sessions and attachments using multi-network simulcasting |
US8644200B2 (en) * | 2004-10-22 | 2014-02-04 | Qualcomm Incorporated | Time multiplexing of unicast and multicast signals on a downlink carrier frequency in a wireless communication system |
US7899451B2 (en) * | 2007-07-20 | 2011-03-01 | Jianhong Hu | OWA converged network access architecture and method |
-
2007
- 2007-07-03 EP EP07012989A patent/EP2011496A1/en not_active Withdrawn
-
2008
- 2008-06-26 AU AU2008271573A patent/AU2008271573B2/en not_active Ceased
- 2008-06-26 CN CN200880023180.8A patent/CN101720223B/zh not_active Expired - Fee Related
- 2008-06-26 CA CA002691943A patent/CA2691943A1/en not_active Abandoned
- 2008-06-26 US US12/667,392 patent/US8211479B2/en not_active Expired - Fee Related
- 2008-06-26 RU RU2009149684/15A patent/RU2478382C2/ru not_active IP Right Cessation
- 2008-06-26 JP JP2010513754A patent/JP5386483B2/ja not_active Expired - Fee Related
- 2008-06-26 KR KR1020097027673A patent/KR101529306B1/ko not_active IP Right Cessation
- 2008-06-26 WO PCT/EP2008/005191 patent/WO2009003631A1/en active Application Filing
-
2009
- 2009-12-31 IL IL203063A patent/IL203063A/en not_active IP Right Cessation
-
2010
- 2010-04-14 NO NO20100528A patent/NO20100528L/no not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005004890A1 (en) * | 2003-07-11 | 2005-01-20 | Indena S.P.A. | Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions |
WO2006042409A1 (en) * | 2004-10-20 | 2006-04-27 | Endorecherche, Inc. | Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women |
WO2006113242A2 (en) * | 2005-04-13 | 2006-10-26 | Unimed Pharmaceuticals, Inc. | Method of increasing testosterone and related steroid concentrations in women |
Non-Patent Citations (1)
Title |
---|
JPN5010008599; STUART FITZSIMMONS: [ONLINE] , 20031205 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016513680A (ja) * | 2013-03-15 | 2016-05-16 | ワーナー チルコット カンパニー, エルエルシーWarner Chilcott Company, Llc | 医薬ソフトゼラチンカプセル剤形 |
Also Published As
Publication number | Publication date |
---|---|
CN101720223A (zh) | 2010-06-02 |
US8211479B2 (en) | 2012-07-03 |
AU2008271573B2 (en) | 2013-03-21 |
EP2011496A1 (en) | 2009-01-07 |
RU2478382C2 (ru) | 2013-04-10 |
WO2009003631A1 (en) | 2009-01-08 |
NO20100528L (no) | 2010-05-19 |
KR101529306B1 (ko) | 2015-06-16 |
JP5386483B2 (ja) | 2014-01-15 |
US20100183751A1 (en) | 2010-07-22 |
CA2691943A1 (en) | 2009-01-08 |
IL203063A (en) | 2014-06-30 |
RU2009149684A (ru) | 2011-07-10 |
CN101720223B (zh) | 2014-03-19 |
KR20100029788A (ko) | 2010-03-17 |
AU2008271573A1 (en) | 2009-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5386483B2 (ja) | 血管作動性物質とエストロゲンとの組合せ、および女性の性機能障害の治療におけるその使用 | |
RU2440127C2 (ru) | Лекарственные формы, полезные для лечения мужской и женской импотенции | |
JP2011079853A (ja) | 男性および女性の***不能の処置に有用な配合剤 | |
JP4892342B2 (ja) | 血管作用物質の組合せおよび性機能不全の治療におけるそれらの使用 | |
PL203555B1 (pl) | Kompozycje farmaceutyczne zawieraj ace ekstrakty Tribulus terrestris, Turnera diffusa, Cinnamon cassia i ekstrakt z Ginkgo biloba oraz ich zastosowanie do wytwarzania leku do leczenia m eskiej i ze nskiej impotencji |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Effective date: 20110527 Free format text: JAPANESE INTERMEDIATE CODE: A621 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130312 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130612 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130813 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130910 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131007 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |